Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
June 2017
-
Media ReleaseNovartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCLAt interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43%…
-
Women in Science: Shilpa Shah-Mehta
-
Media ReleaseNovartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product labelTasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials…
-
Media ReleaseNovartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancerPhase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab) Collaboration expands upon existing clinical investigation of…
-
Media ReleaseNovartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancerCollaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with…
-
Media ReleaseNovartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanomaStudy is longest follow-up to date of a BRAF and MEK inhibitor combination therapy in patients with BRAF V600-mutant metastatic melanoma[1] Study shows stable overall survival and progression-free…
-
Innovating on a trusted class of antibiotics to attack superbugs
A new compound aims to attack dangerous antibiotic-resistant bacteria.
-
Women in Science: Cathryn Clary
Our Global Head of Patient Affairs and Policy shares why it’s critical to engage patients throughout the drug development process.
-
Media ReleaseNovartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancerAt a subsequent analysis of the MONALEESA-2 trial, after nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared…
-
Minion challenges assumptions about the genome
A diminutive protein prompts a closer look at DNA dark matter.
May 2017
-
Media ReleaseProgress reported in global fight against diarrheal disease cryptosporidiosisNovartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process…
-
Media ReleaseSandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines AgencySandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data…
Pagination
- ‹ Previous page
- 1
- …
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- …
- 152
- › Next page